UNICHEM LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 576 INR | -2.14% |
|
+4.78% | +41.91% |
| Sales 2022 | 12.7B 153M | Sales 2023 | 13.43B 161M | Capitalization | 20.35B 244M |
|---|---|---|---|---|---|
| Net income 2022 | 331M 3.98M | Net income 2023 | -2.02B -24.29M | EV / Sales 2022 | 1.42 x |
| Net cash position 2022 | 236M 2.84M | Net Debt 2023 | 1.29B 15.47M | EV / Sales 2023 | 1.61 x |
| P/E ratio 2022 |
55.6
x | P/E ratio 2023 |
-10.1
x | Employees | 2,894 |
| Yield 2022 |
1.54% | Yield 2023 |
-
| Free-Float | 28.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Unichem Laboratories Limited
More press releases
| 1 day | -2.14% | ||
| 1 week | +4.78% | ||
| Current month | +17.06% | ||
| 1 month | +15.66% | ||
| 3 months | +26.40% | ||
| 6 months | +36.54% | ||
| Current year | +41.91% |
1 week
541.95
607.40
1 month
472.75607.40
Current year
416.00607.40
1 year
366.40607.40
3 years
198.00607.40
5 years
80.00607.40
10 years
80.00607.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 23-08-09 | |
Sandip Ghume
DFI | Director of Finance/CFO | - | 18-10-29 |
| Chairman | 71 | 77-08-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pranay Godha
BRD | Director/Board Member | 51 | 23-08-09 |
| Director/Board Member | 75 | - | |
| Chairman | 71 | 77-08-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 576 | -2.14% | 33,346 |
| 24-04-22 | 588.6 | +1.78% | 56,879 |
| 24-04-19 | 578.3 | -0.98% | 80,067 |
| 24-04-18 | 584 | +4.16% | 254,516 |
| 24-04-16 | 560.8 | +2.01% | 44,294 |
Delayed Quote NSE India S.E., April 23, 2024 at 07:51 am EDT
More quotes
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
- Stock Market
- Equities
- UNICHEMLAB Stock
- UNICHEMLAB Stock
